‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra despite VA hurdle

With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease.